Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma.
暂无分享,去创建一个
[1] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[2] T. Choueiri,et al. Non-clear cell renal cell carcinoma, part 2: therapy. , 2015, Clinical advances in hematology & oncology : H&O.
[3] A. Hakimi,et al. Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies , 2015, Front. Oncol..
[4] G. Freeman,et al. PD-L1 expression in nonclear-cell renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] A. Kapoor,et al. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. , 2013, Current oncology.
[6] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Huzarski,et al. Survival in patients with rare subtypes of renal cell carcinoma , 2002, BJU international.
[8] R. Figlin,et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. , 2002, The Journal of urology.